TP53 PIN3 polymorphism associated with breast cancer risk in Iranian women

Indian Journal of Cancer

Volumn 48, Issue 3, 2011, Pages 298-302

  Faghani, M ^a   Ghasemi, F M ^a   Nikhbakht, M ^b   Salehi, M ^b  

^a GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; Iranian women; PIN3 polymorphism; TP53 genotypes

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; BASE PAIRING; BREAST CANCER; CANCER GRADING; CANCER RISK; CANCER SIZE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE DUPLICATION; GENE FREQUENCY; GENOTYPE; HISTOPATHOLOGY; HUMAN; INTRON; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENOTYPE; HUMANS; INTRONS; IRAN; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS; SEGMENTAL DUPLICATIONS, GENOMIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80054009341     PISSN: 0019509X     EISSN: 19984774     Source Type: Journal    
DOI: 10.4103/0019-509X.84925     Document Type: Article

References (36)

1. Williams C, Norberg T, Ahmadian A, Pontén F, Bergh J, Inganäs M, et al. Assessment of sequence-based p53 gene analysis in human breast cancer: Messenger RNA in comparison with genomic DNA targets. Clin Chem 1998;44:455-62. (Pubitemid 28141338)
2. Rahko E, Blanco G, Bloigu R, Soini Y, Talvensaari-Mattila A, Jukkola A. Adverse outcome and resistance to adjuvant antiestrogen therapy in node-positive postmenopausal breast cancer patients-The role of p53. Breast 2006;15:69-75. (Pubitemid 43210552)
3. Soussi T, Béroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat Rev Cancer 2001;1:233-40. (Pubitemid 33741898)
4. Lozano G, Levine AJ. Tissue-specific expression of p53 in transgenic mice is regulated by intron sequences. Mol Carcinog 1991;4:3-9.
5. Bai L, Zhu W-G. P53: Structure, Function and Therapeutic Applications. J Cancer Mol 2006;2:141-53.
6. Gemignani F, Moreno V, Landi S, Moullan N, Chabrier A, Gutiérrez-Enríquez S, et al. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 2004;11;23:1954-6. (Pubitemid 38445422)
7. Zehbe I, Voglino G, Wilander E, Genta F, Tommasino M. Codon 72 polymorphism of p53 and its association with cervical cancer. Lancet 1999;17;354:218-9. (Pubitemid 29329163)
8. Fan R, Wu MT, Miller D, Wain JC, Kelsey KT, Wiencke JK, et al. The p53 codon 72 polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2000;9:1037-42.
9. Soulitzis N, Sourvinos G, Dokianakis DN, Spandidos DA. P53 codon 72 polymorphism and its association with bladder cancer. Cancer Lett 2002;28;179:175-83. (Pubitemid 34215109)
10. Buyru N, Tigli H, Dalay N. P53 codon 72 polymorphism in breast cancer. Oncol Rep 2003;10:711-4.
11. Faghani M, Nikhbakht M, Salehi M, Rabbani M, Talebi A, SoleimanieB, etal. Investigation of p53 codon 72 polymorphism in breast cancer in isfahan. Vol. 84. Isfahan, Iran: Isfahan University of Medical Sciences; 2007. p. 26-33.
12. Pérez LO, Abba MC, Dulout FN, Golijow CD. Evaluation of p53 codon 72 polymorphism in adenocarcinomas of the colon and rectum in La Plata, Argentina. World J Gastroenterol 2006;7;12:1426-9.
13. Tommiska J, Eerola H, Heinonen M, Salonen L, Kaare M, Tallila J, et al. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 2005;11:5098-103. (Pubitemid 41003693)
14. Wu X, Zhao H, Amos CI, Shete S, Makan N, Hong WK, et al. P53 Genotypes and Haplotypes Associated With Lung Cancer Susceptibility and Ethnicity. J Natl Cancer Inst 2002;94:681-90. (Pubitemid 34552489)
15. Buyru N, Altinisik J, Demokan S, Dalay N. P53 genotypes and haplotypes associated with risk of breast cancer. Cancer Detect Prev 2007;31:207-13. (Pubitemid 47248151)
16. Birgander R, Själander A, Rannug A, Alexandrie AK, Sundberg MI, Seidegård J, et al. P53 polymorphisms and haplotypes in lung cancer. Carcinogenesis 1995;16:2233-6.
17. Själander A, Birgander R, Hallmans G, Cajander S, Lenner P, Athlin L, et al. P53 polymorphisms and haplotypes in breast cancer. Carcinogenesis 1996;17:1313-6.
18. Hrstka R, Beranek M, Klocova K, Nenutil R, Vojtesek B. Intronic polymorphisms in TP53 indicate lymph node metastasis in breast cancer. Oncol Rep 2009;22:1205-11.
19. Trifa F, Karray-Chouayekh S, Mabrouk I, Baccouche S, Khabir A, Sellami-Boudawara T, et al. Haplotype analysis of p53 polymorphisms: Arg72Pro, Ins16bp and G13964C in Tunisian patients with familial or sporadic breast cancer. Cancer Epidemiol 2010;34:184-8.
20. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. (Pubitemid 40372904)
21. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics 2005. CA Cancer J Clin 2005;55:10-30.
22. Behjati F, Atri M, Najmabadi H, Nouri K, Zamani M, Mehdipour P. Prognostic value of chromosome 1 and 8 copy number in invasive ductal breast carcinoma among Iranian women: An interphase FISH analysis. Pathol Oncol Res 2005;11:157-63. (Pubitemid 41564562)
23. Atri M, Jafarimojarrad E, Javidroozi M, Mehdipour P. Lack of association between early onset of breast cancer and numbers of affected relatives in an Iranian population. Fam Cancer 2003;2:117-8. (Pubitemid 37247984)
24. Asadpour, [Isfahan: First degree of cancer in Iran], in Jame jam journal 2006;15-16. (In Persian)
25. Khadang B, Fattahi MJ, Talei A, Dehaghani AS, Ghaderi A. Polymorphism of TP53 codon 72 showed no association with breast cancer in Iranian women. Cancer Genet Cytogenet 2007;173:38-42. (Pubitemid 46187296)
26. Kazemi M, Salehi Z, Chakosari RJ. TP53 codon 72 polymorphism and breast cancer in northern Iran. Oncol Res 2009;18:25-30.
27. Powell BL, van Staveren IL, Roosken P, Grieu F, Berns EM, Iacopetta B. Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer. Carcinogenesis 2002;23:311-5. (Pubitemid 34224008)
28. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;17;406:747-52.
29. Brankovic-Magic MV, Jankovic RN, Dobricic JD, Borojevic ND, ZM, Radulovic SS. TP53 mutations in breast cancer: Association with ductal histology and early relapse of disease. Int J Biol Markers 2008;23:147-53.
30. Mahasneh AA, Abdel-Hafiz SS. Polymorphism of p53 gene in Jordanian population and possible associations with breast cancer and lung adenocarcinoma. Saudi Med J 2004;25:1568-73. (Pubitemid 39646625)
31. Zhang Z, Wang M, Wu D, Wang M, Tong N, Tian Y, et al. P53 codon 72 polymorphism contributes to breast cancer risk: A meta-analysis based on 39 case-control studies. Breast Cancer Res Treat 2010;120:509-17.
32. Sayhan N, Yazici H, Budak M, Bitisik O, Dalay N. P53 codon 72 genotypes in colon cancer. Association with human papillomavirus infection. Res Commun Mol Pathol Pharmacol 2001;109:25-34. (Pubitemid 32646073)
33. Lancaster JM, Brownlee HA, Wiseman RW, Taylor J. P53 polymorphism in ovarian and bladder cancer. Lancet 1995;346:182.
34. Wang-Gohrke S, Becher H, Kreienberg R, Runnebaum IB, Chang-Claude J. Intron 3 16 bp duplication polymorphism of p53 is associated with an increased risk for breast cancer by the age of 50 years. Pharmacogenetics 2002;12:269-72. (Pubitemid 34596792)
35. Montazeri A, Ebrahimi M, Mehrdad N, Ansari M, Sajadian A. Delayed presentation in breast cancer: A study in Iranian women. BMC Womens Health 2003;3:4.
36. Weston A, Pan CF, Ksieski HB, Wallenstein S, Berkowitz GS, Tartter PI, et al. P53 haplotype determination in breast cancer. Cancer Epidemiol Biomarkers Prev 1997;6:105-12 (Pubitemid 27069203)